Infections caused by Panton-Valentine leukocidin (PVL)-producing strains of Staphylococcus aureus have been reported with increasing frequency. However, the role of PVL in the pathogenesis of invasive staphylococcal infection is controversial. It is interesting to note that the role played by PVL may depend on the site of infection; although an association between PVL and severity has been reported in lung and bone infection, this is not the case for skin and soft tissue infection. A number of recent reports describe severe complications associated with PVL-producing strains in musculoskeletal infections. This review summarizes the current evidence on the infl uence of PVL on musculoskeletal infections caused by S. aureus in children and highlights areas of uncertainty relating to management.
T he majority of musculoskeletal infections in children are caused by Staphylococcus aureus. In the last decade, infections caused by Panton-Valentine leukocidin (PVL)-producing strains of S.aureus have been reported with increasing frequency. 1 PVL is an exotoxin produced by certain S. aureus strains, which was originally described by Van de Velde in 1894. 2 In 1932, Panton and Valentine suggested that PVL production is responsible for severe staphylococcal infections in humans. 3 The toxin's ability to cause the death of polymorphonuclear cells has been known since its earliest descriptions. The role of PVL in the pathogenesis and development of severe invasive staphylococcal infection in general is controversial. A recent commentary highlighted the absence of evidence for a role of PVL in skin and soft tissue infections but suggested that PVL infl uences the course of staphylococcal infections in lung and bone in an animal model. 4 
DETECTION OF PANTON-VALENTINE LEUKOCIDIN
PVL-producing S. aureus strains are identifi ed either by detection of the genes encoding PVL or the toxin itself. Standard techniques for detecting the pvl gene include nucleic acid amplifi cation using polymerase chain reaction with lukF-PV and lukS-PVspecifi c primers. PVL toxin can be detected by an enzyme-linked immunosorbent assay using antibodies against lukS-PV. 5 Approximately 90% of S. aureus strains that possess pvl produce toxic concentrations of PVL in vitro. 5 Pvl presence is more common in methicillin-resistant S. aureus (MRSA) than in methicillin-sensitive S. aureus (MSSA). However, PVL concentrations produced are not different between pvl-positive MSSA and pvl-positive MRSA. 5, 6 PVL concentrations can be infl uenced by the specifi c S. aureus strain and culture conditions. 5 On the assumption that PVL-producing capacity measured in vitro refl ects in vivo concentrations, quantitative measurement of toxin may be a better prognostic marker than the presence of PVL genes. Rapid tests for PVL detection using either molecular techniques or immunochromatography are being developed 5, 7 and in the future, even faster tests using matrix-assisted laser desorption/ionization time-of-fl ight mass spectrometry may allow PVL detection within minutes. 8 
EPIDEMIOLOGY AND CLINICAL FEATURES
To date, 9 high-quality studies have reported the frequency and/or infl uence of PVL-producing S. aureus in musculoskeletal infections in children. Publications describing only case reports or case series were not included in this review. Six of the 9 studies are from the same tertiary pediatric hospital in Texas; only 2 studies (from France and Greece) have investigated this issue outside the United States. There is considerable variability in the selection of patients included in these studies. Four studies included only patients with osteoarticular infections caused by S. aureus, [9] [10] [11] [12] 4 studies included patients with all types of invasive S. aureus infections 1, [13] [14] [15] and the remaining study included patients with infections caused by PVL-producing S. aureus only. 16 In the studies from the United States, the proportion of MRSA causing musculoskeletal infections was high, ranging from
The Pediatric Infectious Disease Journal • Volume 31, Number 5, May 2012 ESPID Reports and Reviews 53% to 68% with the exception of 1 study investigating primarily patients with septic arthritis in which the proportion of MRSA was lower (36%). The only study outside the United States that included osteoarticular infections caused by both MSSA and MRSA, reported a considerably lower proportion of MRSA (26%). Regardless of the location of the study, the proportion of PVL-producing S. aureus was consistently higher in infections caused by MRSA (74-100%) than those caused by MSSA (9-46%). The overall reported proportion of PVL-producing S. aureus is therefore dependent on the prevalence of MRSA in the respective region and ranged from 37% in Greece to 78% in Texas ( Fig. 1 ).
INFLUENCE OF PANTON-VALENTINE LEUKOCIDIN ON CLINICAL OUTCOME
There was considerable variability in the reported outcome associated with PVLproducing S. aureus (Table 1) . Four of 5 studies reported longer duration of fever, and higher maximal C-reactive protein and erythrocyte sedimentation rate. 1,9-11 All 6 studies that reported the frequency of complications found a higher rate of abscess, pneumonia and deep vein thrombosis (DVT) in children with infections caused by PVL-producing strains of S. aureus. 1, 9, 10, 12, 14, 16 Of the 3 studies that reported length of hospital stay, 1 found a longer duration associated with PVL-producing S. aureus. 1, 16, 17 In the 2 studies that reported length of intensive care unit admission, a longer duration was associated with PVLproducing S. aureus. 1, 9 It is surprising to note that white cell count at presentation was either not different 1, 11, 12 or higher 9 in PVL-producing S. aureus musculoskeletal infections. The proportion of children needing surgical intervention was not different in those with PVL-producing S. aureus in the 3 studies providing this information. 1, 9, 11 In the only study to report the number of interventions per child, PVL-producing S. aureus was associated with a higher number of interventions. 16 
CHOICE OF ANTIBIOTIC TREATMENT
Certain antibiotics increase or decrease PVL production in vitro. 18, 19 For example, oxacillin in subinhibitory concentrations increases PVL production whereas clindamycin, linezolid, fusidic acid and rifampicin have all been shown to decrease PVL production. Although prompt administration of antibiotics associated with decreased PVL production has been advocated 20, 21 and is common clinical practice, no study has shown clinical benefit or compared different regimens. A few guidelines give recommendations for the management of infections caused by PVLproducing S. aureus strains, including the use of clindamycin, linezolid or intravenous immunoglobulin. 21, 22 Some experts suggest including empiric treatment for PVL-producing S. aureus strains for all suspected staphylococcal infections once the local prevalence of MRSA is higher than 10-15%. 23 This approach does not account for the fact that in some regions, a large proportion of PVLproducing S. aureus strains are MSSA. It is important to note, however, that clinical studies comparing the effectiveness of different therapeutic regimens in infections caused by PVL-producing S. aureus are lacking.
INVESTIGATIONS FOR DEEP VENOUS THROMBOSIS
An association between DVT and muscoloskeletal infections caused by PVLproducing S. aureus has been described. 10, 24 The incidence of DVT in this setting has been reported as up to 6%, but is likely to be higher as most studies have not routinely included investigations for this complication. 24 Of particular concern is the possibility that children with infection-associated DVT may develop septic pulmonary emboli with life-threatening consequences. [24] [25] [26] [27] Some authors speculate that septic emboli from a local DVT are responsible for dissemination of infection to the lung and brain. 28 Investigations for thrombophilia are rarely helpful. 28 Most commonly, DVT develops close to the site of infection and therefore the majority of cases are detected incidentally on magnetic resonance imaging studies performed to investigate the extent of the infection or presumed abscess. 24, 27, 28 Other modalities that have been used to detect DVT in this setting include computed tomography scans, ultrasound with Doppler flow or magnetic resonance venography. 25, 28, 29 Although 1 study suggests that the preferred imaging modality is ultrasound with Doppler flow, 24 this investigation may be unreliable as surrounding inflammation may change the venous flow.
The high incidence of DVT in musculoskeletal infections caused by PVLproducing S. aureus and the potential for life-threatening complications warrant careful clinical evaluation and perhaps systematic screening. However, no study has compared the relative sensitivity and specificity of magnetic resonance imaging and ultrasound with Doppler flow for the presence of DVT in this setting, and therefore, the optimal diagnostic approach is unknown.
TREATMENT FOR DEEP VENOUS THROMBOSIS
Therapeutic approaches for infectionassociated DVT include the use of low 
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The Pediatric Infectious Disease Journal • Volume 31, Number 5, May 2012 molecular weight heparin and intravenous unfractionated heparin. 24, 27, 28 In severe cases, thrombectomy or placement of intravascular filters have been described. 24, 25 In the absence of any comparative studies, it is uncertain which of these approaches provides optimal resolution of thrombus and infection, and best prevents dissemination of infection with the lowest complication rate. The optimal duration of treatment and follow-up for infection-associated DVT is also unclear. One study reported resolution of the thrombus after an average of 11 weeks, but only 30% of the children had follow-up imaging studies done. 27 
CONCLUSION
In summary, the current evidence suggests that musculoskeletal infection in children caused by PVL-producing strains of S. aureus is associated with longer duration of fever, more elevated inflammatory markers, higher frequency of complications, longer intensive care unit admission and more frequent surgical intervention. It currently remains unclear whether this information is useful in guiding the management and choice of antibiotic treatment.
